KYORIN Pharmaceutical Co.,Ltd. (JP:4569)
:4569
Want to see JP:4569 full AI Analyst Report?
4569 Stock Chart & Stats
¥1537.00
-¥23.00(-1.53%)
At close: 4:00 PM EST
¥1537.00
-¥23.00(-1.53%)
Day’s Range― - ―
52-Week Range¥1,067.00 - ¥1,725.00
Previous CloseN/A
Volume61.80K
Average Volume (3M)127.03K
Market Cap
¥60.17B
Enterprise Value¥75.23B
Total Cash (Recent Filing)¥16.62B
Total Debt (Recent Filing)¥26.48B
Price to Earnings (P/E)19.0
Beta0.49
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.36%
Share Statistics
EPS (TTM)179.30
Shares Outstanding59,945,640
10 Day Avg. Volume147,840
30 Day Avg. Volume127,030
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)0.66
Price to Sales (P/S)0.75
P/FCF Ratio37.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27
Revenue Forecast (FY)¥124.60B
Bulls Say, Bears Say
Bulls Say
Low Leverage And Conservative Balance SheetA low debt-to-equity (~0.17) and steadily growing equity provide durable financial flexibility. This conservative financing reduces refinancing and interest-rate risk, supports continued R&D and product launches, and permits strategic responses to reimbursement or market shifts without immediate liquidity strain.
Focused Prescription Drug Business ModelA concentrated commercial footprint in prescription medicines for respiratory, infectious and immunology/allergy areas gives predictable, institutional demand and regulatory familiarity. The focused product portfolio in Japan supports steady revenue streams and allows targeted R&D and marketing investments with clearer ROI horizons.
Improving Operating Cash Flow And Positive FCF In FY2026The swing to positive operating cash flow (~¥6.4B) and FCF (~¥2.5B) indicates recent improvement in cash generation capacity. If sustained, this strengthens internal funding for clinical programs, capex, dividends or bolt-on deals, reducing reliance on external financing and supporting long-term value creation.
Bears Say
Significant Margin Compression In FY2026Material declines in gross and net margins weaken intrinsic profitability and return on invested capital. Lower margins reduce funds available for R&D and commercial support, heighten sensitivity to cost inflation or pricing pressure under Japan's reimbursement system, and can undermine long-term competitive reinvestment.
Revenue Contracted In FY2026A noticeable year-over-year revenue decline interrupts prior growth trends and may reflect product lifecycle, pricing or demand headwinds. Persisting revenue weakness would erode scale advantages, reduce margin recovery potential, and constrain funding for clinical development and commercialization over coming quarters.
Volatile Free-cash-flow And Modest Cash ConversionSwinging free cash flow and weak conversion from earnings signal uneven working-capital management or lumpy investment timing. This volatility complicates capital allocation, increases the chance of external financing needs during downturns, and reduces confidence in sustaining dividends or funding pipeline investments.
KYORIN Pharmaceutical Co.,Ltd. News
4569 FAQ
What was KYORIN Pharmaceutical Co.,Ltd.’s price range in the past 12 months?
KYORIN Pharmaceutical Co.,Ltd. lowest stock price was ¥1067.00 and its highest was ¥1725.00 in the past 12 months.
What is KYORIN Pharmaceutical Co.,Ltd.’s market cap?
KYORIN Pharmaceutical Co.,Ltd.’s market cap is ¥60.17B.
When is KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date?
KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date is Jul 30, 2026 which is in 34 days.
How were KYORIN Pharmaceutical Co.,Ltd.’s earnings last quarter?
KYORIN Pharmaceutical Co.,Ltd. released its earnings results on May 12, 2026. The company reported -¥11.68 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.68.
Is KYORIN Pharmaceutical Co.,Ltd. overvalued?
According to Wall Street analysts KYORIN Pharmaceutical Co.,Ltd.’s price is currently Overvalued.
Does KYORIN Pharmaceutical Co.,Ltd. pay dividends?
KYORIN Pharmaceutical Co.,Ltd. pays a Semiannually dividend of ¥9.922 which represents an annual dividend yield of 3.36%. See more information on KYORIN Pharmaceutical Co.,Ltd. dividends here
What is KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate?
KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KYORIN Pharmaceutical Co.,Ltd. have?
KYORIN Pharmaceutical Co.,Ltd. has 59,945,640 shares outstanding.
What happened to KYORIN Pharmaceutical Co.,Ltd.’s price movement after its last earnings report?
KYORIN Pharmaceutical Co.,Ltd. reported an EPS of -¥11.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.259%.
Which hedge fund is a major shareholder of KYORIN Pharmaceutical Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:4569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KYORIN Pharmaceutical Co.,Ltd.
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---